Michael Misialek

About Michael Misialek

Michael, Associate Chair of Pathology at Newton-Wellesley Hospital, says, “The most interesting moment in my career was doing an autopsy several years ago on a young man who died of metastatic lung cancer. He was a non-smoker and was among the first patients ever to be identified with an ALK translocation and was enrolled in the first trial in the world for ALK targeted therapy, for what would later be approved as Crizotinib. The findings would advance our knowledge of targeted therapy resistance. I consider him a hero and early pioneer of precision medicine. He taught me the role pathologists play in precision medicine.”